Physician profile
Thomas P Stern
NPI 1083639439
$31,115.98
in general payments reported to CMS, 2019-2025
31 companies · $14K in 2025
The $14K reported for 2025 was more than what 94% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $662 · 2020: $1,480 · 2021: $532 · 2022: $886 · 2023: $9,505 · 2024: $3,718 · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $9,500 · Honoraria: $7,600 · Consulting Fee: $3,680 · Travel and Lodging: $3,675 · Food and Beverage: $3,101.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $9,500.00 |
| Honoraria | $7,600.00 |
| Consulting Fee | $3,680.00 |
| Travel and Lodging | $3,674.89 |
| Food and Beverage | $3,100.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avadel Cns Pharmaceuticals, LLC | $23,411.53 | 2023-2025 | Lumryz |
| Glaxosmithkline, LLC. | $1,956.99 | 2019-2025 | Nucala, Arexvy, Trelegy Ellipta |
| Chiesi USA, INC. | $1,557.81 | 2023 | |
| Harmony Biosciences LLC | $1,354.72 | 2020-2023 | Wakix |
| Astrazeneca Pharmaceuticals LP | $730.09 | 2019-2025 | Airsupra, Fasenra, Breztri |
| Inspire Medical Systems, INC. | $538.87 | 2022-2025 | Inspire |
| Jazz Pharmaceuticals INC. | $496.86 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $259.56 | 2019 | |
| Axsome Therapeutics, INC. | $120.73 | 2023-2025 | Sunosi |
| Fisher & Paykel Healthcare INC | $104.55 | 2020-2025 | Fisher & Paykel Healthcare |
| Novo Nordisk INC | $102.66 | 2019-2024 | Wegovy, Saxenda |
| Regeneron Healthcare Solutions, INC. | $69.18 | 2023-2024 | Dupixent |
| Inogen, INC. | $67.14 | 2022-2023 | Inogen One G5 Oxygen Concentrator - Bluetooth, Inogen At Home Stationary Concentrator |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.63 | 2019-2023 | Stiolto Respimat |
| Philips North America LLC | $47.01 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Resmed Corp | $40.00 | 2024 | |
| Lilly USA, LLC | $37.18 | 2023-2024 | Zepbound |
| Genzyme Corporation | $33.41 | 2025 | |
| Lundbeck LLC | $30.82 | 2023 | Vyepti |
| Sanofi-Aventis U.S. LLC | $29.00 | 2021 | |
| Insmed, INC. | $26.09 | 2025 | Arikayce |
| Mylan Specialty L.P. | $20.45 | 2023 | Yupelri |
| Azurity Pharmaceuticals, INC. | $18.34 | 2025 | Horizant |
| Paratek Pharmaceuticals, INC. | $12.36 | 2022 |
7 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Stern listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.